EICHOR
● Completed
Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults
Condition: Acne Vulgaris · Sponsor: Biofrontera Inc.
About this study
The aim of this study is to test the safety and efficacy of photodynamic therapy (PDT) for the medication Ameluz® performed with the PDT-lamp BF-RhodoLED® in comparison to the respective placebo treatment for moderate to severe Acne vulgaris.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (9)
| First OC Dermatology | Fountain Valley, California, United States | — |
| Cosmetic Laser Dermatology | San Diego, California, United States | — |
| Dermatology Associates PA of the Palm Beaches | Delray Beach, Florida, United States | — |
| ForCare Clinical Research | Tampa, Florida, United States | — |
| DelRicht Research | Baton Rouge, Louisiana, United States | — |
| Skin Search of Rochester, Inc | Rochester, New York, United States | — |
| Clinical Research Center of the Carolinas | Charleston, South Carolina, United States | — |
| DermResearch PA | Austin, Texas, United States | — |
| Austin Institute for Clinical Research Inc. | Pflugerville, Texas, United States | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05080764